Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 3, 2011, Pages 325-341

  Lee, James A ^a   Shaheen, Megan ^b   Walke, Thomas ^a   Daly, Matt ^a  

^a ALTARUM INSTITUTE   (United States)

^b Altarum Institute   (United States)

Author keywords

breast neoplasms; economic models; HER2 protein; immunohistochemistry; in situ hybridization; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ACCURACY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH ECONOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; WOMEN'S HEALTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RECEPTOR, ERBB-2;

EID: 79959264015     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.25     Document Type: Article

References (78)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006)
2. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3, 237-252 (1998)
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235, 177-182 (1987)
4. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989)
5. Bilous M, Ades C, Armes J et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 12, 92-98 (2003)
6. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291, 1972-1977 (2004)
7. Leyland JB. Trastuzumab: hope and realities. Lancet Oncol. 3, 137-144 (2002)
8. Albanell J, Codony J, Rovira A et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532, 253-268 (2003)
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001)
10. Dendukuri N, Khetani K, McIsaac M et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176, 1429-1434 (2007)
11. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J. Clin. Oncol. 22, 322-329 (2004)
12. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25. 118-145 (2007)
13. Mass R, Press M, Anderson S et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240-246 (2005)
14. Press M, Sauter G, Bernstein L et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11, 6598-6607 (2005)
15. Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br. J. Cancer 88, 1587-1591 (2003)
16. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am. J. Clin. Pathol. 123, 237-243 (2005)
17. Gupta D, Middleton LP, Whitaker MJ et al. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am. J. Clin. Pathol. 119, 381-387 (2003)
18. Loring P, Cummins R, O'Grady A et al. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl. Immunohistochem. Mol. Morphol. 13, 194-200 (2005)
19. Garcia-Caballero T, Grabau D, Green AR et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56, 472-480 (2010)
20. Pedersen M, Rasmussen B. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn. Mol. Pathol. 18, 96-102 (2009)
21. Papouchado BG, Myles J, Lloyd RV et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am. J. Surg. Pathol. 34(6), 767-776 (2010)
22. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl. Immunohistochem. Mol. Morphol. 17, 1-7 (2009)
23. Blank PR, Schwenkglenks M, Moch H et al. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res. Treat. 124(2), 497-507 (2010)
24. Lidgren M, Jönsson B, Rehnberg C et al. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann. Oncol. 19, 487-495 (2008)
25. Ferrusi IL, Marshall DA, Kulin NA et al. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per. Med. 6, 193-215 (2009)
26. Phillips KA, Marshall DA, Haas JS et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 115, 5166-5174 (2009)
27. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 25, 625-633 (2007)
28. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod. Pathol. 18, 1015-1021 (2005).
29. Dietel M, Ellis IO, Höfler H et al. Comparison of automated silver enhanced in situ hybridization (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 451, 19-25 (2007)
30. Shousha S, Peston D, Amo-Takyi B et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54, 248-253 (2009)
31. Vera-Román JM, Rubio-Martínez LA. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch. Pathol. Lab. Med. 128, 627-633 (2004)
32. Lebeau A, Deimling D, Kaltz C et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 19, 354-363 (2001)
33. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 199, 418-423 (2003)
34. Di Palma S, Collins N, Faulkes C et al. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J. Clin. Pathol. 60, 1067-1068 (2007)
35. Le Q, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 115(3), 489-498 (2009)
36. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323-1333 (2009)
37. Press M, Finn R, Cameron D et al. HER2 gene amplification, HER2 and EGFR messenger RNA and protein expression and lapatinib efficacy in women with metastatic breast cancer. Clin. Cancer Res. 14, 7861-7870 (2008)
38. Tong KB, Chen E, Gregory C, Kim D. HER-2 testing and trastuzumab use in the Medicare population. Presented at: 2007 Breast Cancer Symposium. San Francisco, CA, USA, 7-8 September 2007.
39. Ashok M, Griffin P, Halpern M. Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer. Cancer Investig. 28, 735-742 (2010)
40. Ainsworth R, Bartlett JM, Going JJ et al. IHC for HER2 with CBE356 antibody is a more accurate predictor of HER2 gene amplification by FISH than HercepTest in breast carcinoma. J. Clin. Pathol. 58, 1086-1090 (2005)
41. Bartlett JM, Going JJ, Mallon EA et al. Evaluating HER2 amplification and overexpression in breast cancer. J. Pathol. 195, 422-428 (2001)
42. Ciampa A, Xu B, Ayata G, Baiyee D. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl. Immunohistochem. Mol. Morphol. 14, 132-137 (2006)
43. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am. J. Clin. Pathol. 123, 766-770 (2005)
44. Dybdal N, Leiberman G, Anderson S et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res. Treat. 93, 3-11 (2005)
45. Elkin EB, Weinstein MC, Winer EP et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 22, 854-863 (2004)
46. Ellis CM, Dyson MJ, Stephenson TJ et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J. Clin. Pathol. 58, 710-714 (2005)
47. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in situ hybridization in the HER2 testing algorithm. Mod. Pathol. 19, 481-487 (2006)
48. Hoang MP, Sahin AA, Ordonez NG et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am. J. Clin. Pathol. 113, 852-859 (2000)
49. Hofmann M, Stoss O, Gaiser T et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J. Clin. Pathol. 61, 89-94 (2008)
50. Kakar S, Puangsuvan N, Stevens JM et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol. Diagn. 5, 199-207 (2000)
51. Lal P, Salazar PA, Hudis CA et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2279 cases and comparison of dual-color and single-color scoring. Am. J. Clin. Pathol. 121, 631-636 (2004)
52. McCormick SR, Lillemoe TJ, Beneke J et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am. J. Clin. Pathol. 117, 935-943 (2002)
53. Mrozkowiak A, Olszewski WP, Piascik A et al. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol. J. Pathol. 55, 165-171 (2004)
54. Ogura H, Akiyama F, Kasumi F et al. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer 10, 234-240 (2003)
55. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 5, 63-69 (2004)
56. Perez EA, Roche PC, Jenkins RB et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Clin. Proc. 77, 148-154 (2002)
57. Pothos A, Plastira K, Plastiras A et al. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem. Cytochem. 41, 59-64 (2008).
58. Prati R, Apple SK, He J et al. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 11, 433-439 (2005)
59. Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095-3105 (2002)
60. Reddy JC, Reimann JD, Anderson SM et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin. Breast Cancer 7, 153-157 (2006)
61. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod. Pathol. 13, 866-873 (2000)
62. Saez A, Andreu FJ, Segui MA et al. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer - a study of two hundred cases. Breast 15, 519-527 (2006)
63. Simon R, Nocito A, Ḧbscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 93, 1141-1146 (2001)
64. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 157, 1467-1472 (2000)
65. Tawfik OW, Kimler BF, Davis M et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 48, 258-267 (2006)
66. Tsuda H, Akiyama F, Terasaki H et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92, 2965-2874 (2001)
67. Varshney D, Zhou YY, Geller SA. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am. J. Clin. Pathol. 121, 70-77 (2004)
68. Wang S, Saboorian MH, Frenkel EP et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am. J. Clin. Pathol. 116, 495-503 (2001)
69. Wang S, Saboorian MH, Frenkel EP et al. Assessment of HER-2/neu status in breast cancer. Automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am. J. Clin. Pathol. 116, 495-503 (2001)
70. Willmore C, Holden JA, Layfield LJ. Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay. Appl. Immunohistochem. Mol. Morphol. 13, 333-341 (2005)
71. Gong Y, Sweet W, Duh YJ et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am. J. Clin. Pathol. 131, 490-497 (2009)
72. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J. Mol. Histol. 35, 647-653 (2004)
73. Isola J, Tanner M, Forsyth A et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 10, 4793-4798 (2004)
74. Li-Ning TE, Ronchetti R, Torres-Cabala C et al. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int. J. Surg. Pathol. 13, 343-351 (2005)
75. van de Vijver M, Bilous M, Hanna W et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 9, R68 (2007)
76. Wixom CR, Albers EA, Weidner N. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Appl. Immunohistochem. Mol. Morphol. 12, 248-251 (2004)
77. Zhao J, Wu R, Au A et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod. Pathol. 15, 657-665 (2002)
78. Sung WJ, Park SJ, Gu MJ et al. Automated silver-enhanced in situ hybridization for evaluation of HER2 gene status in breast carcinoma: comparison with fluorescence in situ hybridization and immunohistochemistry. Korean J. Pathol. 44, 28-34 (2010).